First human tests begin for experimental cancer drug targeting multiple tumor types
NCT ID NCT05983133
Summary
This early-stage study is testing a new drug called PF-08046052/SGN-EGFRd2 in people with advanced solid tumors that have spread or cannot be removed by surgery. The main goal is to find the safest dose and understand side effects in 65 participants with specific cancers including colorectal, lung, head and neck, and pancreatic cancers. The study will also gather initial information about whether the drug might help control these cancers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Atrium Health Wake forest Baptist
Winston-Salem, North Carolina, 27157, United States
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
Huntsman Cancer Hospital, University of Utah
Salt Lake City, Utah, 84112, United States
-
Huntsman Cancer Institute, University Of Utah
Salt Lake City, Utah, 84112, United States
-
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Karmanos Cancer Institute Weisberg Cancer Treatment Center
Farmington Hills, Michigan, 48334, United States
-
MD Anderson Cancer Center - University of Texas
Houston, Texas, 77030, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Moffitt Cancer Center McKinley Hospital
Tampa, Florida, 33612, United States
-
Providence Cancer Institute Franz Clinic
Portland, Oregon, 97213, United States
-
Providence Portland Medical Center
Portland, Oregon, 97213, United States
-
Ronald Reagan UCLA Medical Center
Los Angeles, California, 90095, United States
-
Santa Monica UCLA Medical Center & Orthopaedic Hospital
Santa Monica, California, 90404, United States
-
The Christie NHS Foundation Trust
Manchester, M20 4BX, United Kingdom
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
UCLA Hematology/Oncology
Los Angeles, California, 90095, United States
-
UCLA Hematology/Oncology - Santa Monica
Santa Monica, California, 90404, United States
-
University College London Hospital, NIHR UCLH Clinical Research Facility
London, W1T 7HA, United Kingdom
-
University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106, United States
-
University of Iowa
Iowa City, Iowa, 52242, United States
-
University of Utah
Salt Lake City, Utah, 84112, United States
-
Wake Forest Baptist Medical Center / Wake Forest University
Winston-Salem, North Carolina, 27157, United States
Conditions
Explore the condition pages connected to this study.